Literature DB >> 34026275

Anaesthetic management of a known or suspected malignant hyperthermia susceptible patient.

P K Gupta1,2, J G Bilmen1,2, P M Hopkins1,2.   

Abstract

Entities:  

Keywords:  anaesthesia; malignant hyperthermia; myopathy

Year:  2021        PMID： 34026275      PMCID： PMC8134759          DOI： 10.1016/j.bjae.2021.01.003

Source DB:  PubMed          Journal:  BJA Educ        ISSN： 2058-5349


× No keyword cloud information.
  17 in total

1.  Evaluation of personal, environmental and biological exposure of paediatric anaesthetists to nitrous oxide and sevoflurane.

Authors:  N Raj; K A Henderson; J E Hall; I M Aguilera; M Harmer; A Hutchings; B Williams
Journal:  Anaesthesia       Date:  2003-07       Impact factor: 6.955

2.  Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia.

Authors:  A F Nimmo; A R Absalom; O Bagshaw; A Biswas; T M Cook; A Costello; S Grimes; D Mulvey; S Shinde; T Whitehouse; M D Wiles
Journal:  Anaesthesia       Date:  2018-10-31       Impact factor: 6.955

3.  Low anaesthetic waste gas concentrations in postanaesthesia care unit: A prospective observational study.

Authors:  Sebastian Heiderich; Christian Thoben; Nils Dennhardt; Wolfgang Koppert; Terence Krauß; Robert Sümpelmann; Stefan Zimmermann; Werner Klingler
Journal:  Eur J Anaesthesiol       Date:  2018-07       Impact factor: 4.330

4.  Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.

Authors:  M R Weglinski; D J Wedel; A G Engel
Journal:  Anesth Analg       Date:  1997-05       Impact factor: 5.108

5.  Investigating the genetic susceptibility to exertional heat illness.

Authors:  Lois Gardner; Dorota M Miller; Catherine Daly; Pawan K Gupta; Carol House; Daniel Roiz de Sa; Marie-Anne Shaw; Philip M Hopkins
Journal:  J Med Genet       Date:  2020-02-13       Impact factor: 6.318

6.  5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors.

Authors:  J J Pandit; J Andrade; D G Bogod; J M Hitchman; W R Jonker; N Lucas; J H Mackay; A F Nimmo; K O'Connor; E P O'Sullivan; R G Paul; J H M G Palmer; F Plaat; J J Radcliffe; M R J Sury; H E Torevell; M Wang; J Hainsworth; T M Cook
Journal:  Br J Anaesth       Date:  2014-09-09       Impact factor: 9.166

Review 7.  Genomic Screening for Malignant Hyperthermia Susceptibility.

Authors:  Leslie G Biesecker; Robert T Dirksen; Thierry Girard; Philip M Hopkins; Sheila Riazi; Henry Rosenberg; Kathryn Stowell; James Weber
Journal:  Anesthesiology       Date:  2020-12-01       Impact factor: 7.892

8.  Preparation of the Dräger Fabius anesthesia machine for the malignant-hyperthermia susceptible patient.

Authors:  Joel B Gunter; John Ball; Sean Than-Win
Journal:  Anesth Analg       Date:  2008-12       Impact factor: 5.108

9.  Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.

Authors:  N Dlamini; N C Voermans; S Lillis; K Stewart; E-J Kamsteeg; G Drost; R Quinlivan; M Snoeck; F Norwood; A Radunovic; V Straub; M Roberts; A F J E Vrancken; W L van der Pol; R I F M de Coo; A Y Manzur; S Yau; S Abbs; A King; M Lammens; P M Hopkins; S Mohammed; S Treves; F Muntoni; E Wraige; M R Davis; B van Engelen; H Jungbluth
Journal:  Neuromuscul Disord       Date:  2013-04-28       Impact factor: 4.296

10.  Sevoflurane may not be a complete sigh of relief in COVID-19.

Authors:  Vikas Kaura; Philip M Hopkins
Journal:  Br J Anaesth       Date:  2020-09-16       Impact factor: 9.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.